PDF herunterladen
Dialyse aktuell 2019; 23(05): 202-203
DOI: 10.1055/a-0886-1252
Expertentipp
© Georg Thieme Verlag Stuttgart · New York

Autosomal-dominante polyzystische Nierenerkrankung (ADPKD)

Tolvaptan als erste gezielte Therapie bei polyzystischer Nierenerkrankung
Simon Oehm
,
Franziska Grundmann
,
Roman-Ulrich Müller
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
19. Juni 2019 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Die autosomal-dominante polyzystische Nierenerkrankung (ADPKD) ist die häufigste zu einer terminalen Niereninsuffizienz führende genetische Erkrankung. Bis zu 10 % aller europäischen DialysepatientInnen leiden an einer ADPKD [1].

 

  • Literatur

  • 1 Spithoven EM, Kramer A, Meijer E. et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 2014; 29 Suppl. (Suppl. 04) iv15-iv25 doi:10.1093/ndt/gfu017
    CrossrefPubMedSuche in Google Scholar
  • 2 Chapman AB, Devuyst O, Eckardt KU. et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2015; 88: 17-27 doi:10.1038/ki.2015.59
    CrossrefPubMedSuche in Google Scholar
  • 3 Müller RU, Benzing T. Management of autosomal-dominant polycystic kidney disease-state-of-the-art. Clin Kidney J 2018; 11 Suppl (Suppl. 01) i2-i13 doi:10.1093/ckj/sfy103
    CrossrefPubMedSuche in Google Scholar
  • 4 Torres VE, Chapman AB, Devuyst O. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. Supplementary Appendix. N Engl J Med 2012; 367: 2407-2418 doi:10.1056/NEJMoa1205511
    CrossrefPubMedSuche in Google Scholar
  • 5 Chebib FT, Perrone RD, Chapman AB. et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol 2018; 29: 2458-2470 doi:10.1681/ASN.2018060590
    CrossrefPubMedSuche in Google Scholar
  • 6 Müller RU, Haas CS, Sayer JA. Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan. Clin Kidney J 2018; 11: 62-69 doi:10.1093/ckj/sfx071
    CrossrefPubMedSuche in Google Scholar
  • 7 Gansevoort RT, Arici M, Benzing T. et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 2016; 31: 337-348 doi:10.1093/ndt/gfv456
    CrossrefPubMedSuche in Google Scholar
  • 8 Cornec-Le Gall E, Audrézet MP, Rousseau A. et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 2015; 27: 942-951 doi:10.1681/ASN.2015010016
    PubMedSuche in Google Scholar
  • 9 Grantham JJ, Torres VE, Chapman AB. et al. Volume Progression in Polycystic Kidney Disease. N Engl J Med 2006; 354: 2122-2130 doi:10.1056/NEJMoa054341
    CrossrefPubMedSuche in Google Scholar
  • 10 Pei Y, Obaji J, Dupuis A. et al. Unified Criteria for Ultrasonographic Diagnosis of ADPKD. J Am Soc Nephrol 2009; 20: 205-212 doi:10.1681/ASN.2008050507
    CrossrefPubMedSuche in Google Scholar
  • 11 Torres VE, Chapman AB, Devuyst O. et al. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 2017; 377: 1930-1942 doi:10.1056/NEJMoa1710030
    CrossrefPubMedSuche in Google Scholar
  • 12 Torres VE, Abebe KZ, Schrier RW. et al. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 2017; 91: 493-500 doi:10.1016/j.kint.2016.10.018
    CrossrefPubMedSuche in Google Scholar